ArticleJournal of gastroenterology2017
Development of a scoring system for differentiating IgG4-related sclerosing cholangitis from primary sclerosing cholangitis.
Article in Journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- IgG4-related disease in gastroenterology: from pathogenesis to clinical management and long-term outcomes.Journal of gastroenterology · 2026Review
- Endo-hepatology: Bridging the gap between lumen and liver.World journal of gastroenterology · 2025Review
- An atypical case of isolated immunoglobulin G4-related sclerosing cholangitis with a cholangiogram resembling primary sclerosing cholangitis.Clinical journal of gastroenterology · 2024Article
- Clinical Significance of Serum IgG4 in the Diagnosis and Treatment Response of IgG4-Related Disease in Adults of Southwest China: A Retrospective Study.Annals of laboratory medicine · 2023Article
- Autoimmune Pancreatitis and Immunoglobulin G4-related Sclerosing Cholangitis: Past, Present, and Future.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2022Review
- Serum IgG4 cut-off of 70 mg/dL is associated with a shorter time to cirrhosis decompensation and liver transplantation in primary sclerosing cholangitis patients.Canadian liver journal · 2022Article
- Role of Endoscopic Procedures in the Diagnosis of IgG4-Related Pancreatobiliary Disease.Chonnam medical journal · 2021Review
- IgG4-Related Sclerosing Cholangitis: Rarely Diagnosed, but not a Rare Disease.Canadian journal of gastroenterology & hepatology · 2021Review
- Review of primary sclerosing cholangitis with increased IgG4 levels.World journal of gastroenterology · 2020Review
- [Recent Updates of Immunoglobulin G4-related Pancreatobiliary Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2020Review
- [Expression of serum IgG4 in patients with non-IgG4-related hepatobiliary diseases].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020Article
- Primary sclerosing cholangitis with increased immunoglobulin G4 levels: A case report.Medicine · 2019Article
- A good response to steroid therapy in IgG4-related sclerosing cholangitis: a case report.Clinical and experimental hepatology · 2018Article
- Differential diagnostic roles of the serum CA19-9, total bilirubin (TBIL) and the ratio of CA19-9 to TBIL for benign and malignant.Journal of Cancer · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent research has shown that a substantial number of patients with primary sclerosing cholangitis (PSC) can also have elevated serum/tissue IgG4. The aim of our study was to develop a simple scoring system for the discrimination of IgG4-related sclerosing cholangits (IgG4-SC) from PSC.
methodsPatients with IgG4-SC (n = 39) and PSC (n = 76) who had intrahepatic/hilar strictures were included. Candidate-differentiating variables included patient age, other organ involvement (OOI), inflammatory bowel disease, serum IgG4, and cholangiographic features. A scoring system was developed on the basis of these variables, and its performance was internally validated using a bootstrapping-based method.
resultsThe scoring system in the final model included age (<30 years, 0 points; 30-39 years, 1 point; 40-49 years, 2 points; 50-59 years, 3 points; ≥60 years, 4 points), OOI (no, 0 points; yes, 3 points), and beaded appearance (yes, 0 points; no, 2 points). The patients were classified according to their total score into three categories: 0-4 points, probable PSC; 5-6 points, indicating diagnostic steroid trial; 7-9 points, probable IgG4-SC. The discrimination between IgG4-SC and PSC using the scoring system was excellent (area under the receiver operating characteristic curve, 0.986).
conclusionsA reliable differentiation of IgG4-SC from PSC can be made using the scoring system presented here. We suggest the diagnosis of IgG4-SC at a cutoff of 7 points or higher and the indication of diagnostic steroid trial at 5 or 6 points. External validation of our scoring system is warranted.
Indexed as
Identifiers
27470434What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.